Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Two-period Crossover Study in Healthy Male Subjects to Evaluate the Pharmacodynamic Effect of Darexaban (YM150) on Acetyl Salicylic Acid (ASA) and of Darexaban on the Combination of ASA and Clopidogrel at Steady State

NCT01409616 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT01409616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01409616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Two-period Crossover Study in Healthy Male Subjects to Evaluate the Pharmacodynamic Effect of Darexaban (YM150) on Acetyl Salicylic Acid (ASA) and of Darexaban on the Combination of ASA and Clopidogrel at Steady State
Lead sponsor
Astellas Pharma Inc
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2009
Completion date
September 30, 2009
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy subjects, pharmacodynamic interaction